SERB Specialty Pharmaceuticals

SERB Specialty Pharmaceuticals is a global pharmaceutical group with essential products available in over 80 countries through a direct presence in Europe, US, the Middle East, Australia and our broad worldwide network of distributors. Our portfolio is focused on two key franchises: o CRITICAL CARE: • EMERGENCY CARE: wide range of lifesaving medical countermeasures and intensive care medicines. • SURGERY: drugs and devices for supportive care as well as diagnostic agents. o RARE DISEASES: • NEUROLOGY: treatments for rare and severe epileptic and neuromuscular conditions. • METABOLIC DISORDERS: medicines for paediatric inborn errors of metabolism. In 2020, we have strengthened our neurology and rare diseases portfolio with the strategic acquisition of Veriton Pharma (veritonpharma.com) in the UK. In 2021, we have enlarged our critical care medicines portfolio with the acquisition of BTG Specialty Pharmaceuticals (www.btgsp.com) and established our direct presence in US. We are committed to bringing further innovative solutions into the market by accelerating our acquisitions and enhancing our R&D pipeline. #proudtosavelives